DIMERIX LIMITED — Capital/Financing Update 2008

Aug 13, 2008

==> picture [228 x 84] intentionally omitted <==

14 August 2008

The Manager Company Announcements Platform ASX Limited

Dear Sir/Madam,

Renounceable Rights Issue

The Directors of Sun Biomedical Limited confirm that transaction confirmation statements in relation to the Company’s renounceable Rights Issue have been dispatched to Shareholders and Optionholders today.

Please see attached letter sent to shareholders together with their transaction confirmation statements.

For further information see www.sunbiomed.com or contact:

Jim Hallam Director Mobile: 0414 965 442

Sun Biomedical Limited ABN 18 001 285 230

Investor Communications +61 1300 850 505 | F: E: info@sunbiomed.com

Computershare T: +61 1300 850 505 | F: +61 3 9473 2500 |

ASX:SBN www.sunbiomed.com

==> picture [228 x 84] intentionally omitted <==

14 August 2008

Shareholder Shareholder address

Dear Sir/Madam

Issue of New Ordinary Shares and Options under the Renounceable Rights Issue

On behalf of the Company I would like to thank you for your participation in the Sun Biomedical Limited renounceable Rights Issue. The Rights Issue successfully raised in excess of the $2 million Minimum Subscription, and the Company is currently in the process of raising additional funds in accordance with the Shortfall under the Rights Issue up to the Maximum Subscription of $3.2 million.

The funds raised under the Rights Issue will enable the Company to pursue its objectives as set out in the Prospectus. In particular, the Company proposes to apply the significant cash injection as follows:

• (a) the payment of amounts owing in relation to the Company’s acquisition of Sun Biomedical Laboratories, Inc ( SBL );

• (b) the commercialisation of the Chinese joint venture with SiYi, including the capital expenditure required to increase the production capacity at the existing plant to accommodate a higher volume of sales;

• (c) the development of the BioScreens Cup and the cost of attaining FDA 510(k) Clearance for point-of-care sale of the VisuaLine product;

• (d) the development and marketing of OraLine VIII;

• (e) developing SBL’s compliance with Good Manufacturing Practices; and

• (f) working capital to support the ongoing business activities of the Company.

Please find enclosed your transaction confirmation statement following your participation in the Rights Issue.

Yours faithfully

==> picture [82 x 49] intentionally omitted <==

Jim Hallam Director Sun Biomedical Investor Communications ASX:SBN Limited Computershare T: +61 1300 850 505 | F: +61 3 9473 2500 | www.sunbiomed.com ABN 18 001 285 230 E: info@sunbiomed.com